Navigation Links
UCSD study reveals the regulatory mechanism of key enzyme
Date:9/20/2007

Research conducted at the University of California, San Diego (UCSD) School of Medicine has shed new light on the structure and function of one of the key proteins in all mammalian cells, protein kinase A (PKA), an enzyme which plays an essential role in memory formation, communication between nerve cells, and cardiac function.

Utilizing a process called x-ray crystallography, the scientists solved the structure of the large PKA complex, revealing a totally new structure that shows PKAs amazing ability to function as a scaffold, that supports and controls the release of chemicals involved in transmitting signals. The structure is shown in the September 21 issue of the journal Cell, featuring the study that describes the dynamic regulatory subunit of PKA.

PKA belongs to a large superfamily of proteins whose activity is regulated by an important small molecule, cyclic AMP (cAMP), in the cell. Protein kinases transmit chemical signals within the cell to regulate a host of functions, such as cell growth or metabolism. Certain protein kinases have been implicated in the uncontrolled growth of cells; for example, when PKA somehow stays on, its prolonged activation can lead to cardiac disease and breast cancer.

By revealing its highly accurate three-dimensional structure, the UCSD scientists have shown how PKA is inhibited and activated by cAMP. PKA contains two components, the regulatory and catalytic subunits. When the subunits are together in the absence of cAMP, the signaling is turned off; when the two parts break apart after being activated by cAMP, PKA is turned on.

We knew how the two subunits, the catalytic and regulatory subunits, looked as separate entities. But we didnt understand how they actually fit together and are activated by cAMP until we saw this structure, said Susan Taylor, Ph.D., Howard Hughes Medical Institute Investor and professor of pharmacology at UCSD School of Medicine, who headed the study.
'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...ptember 5, 2008Private Medicare Advantage (MA) pla...nrollee in 2008 compared to what the same enrollee...or-service program, according to a new report from...tions to MA plans mandated by the Medicare Improve...A) scheduled to take effect beginning in 2010 ha...
(Date:9/4/2008)...ence of instructions they say could help doctors e...lthDay News) -- Vaccine safety experts say that al...eive vaccinations with close monitoring and a set ...ptember issue of Pediatrics , a team of experts l...h a step-by-step set of instructions -- an algorit...
(Date:9/4/2008)... Medelis, an oncology contract research organ...linical Trials: A Nuanced Approach to Get Into the...cGarry, a preclinical research scientist with 35 y...ical studies are commonly viewed as straightforwar...o operate without true integration with preclinica...
(Date:9/4/2008)... of Palestinian and Israeli teenagers, art from,Ar...wire/ -- America must take a major,role in finding...he world,says Ira Magaziner, chair of the William...ior White House Advisor for Policy Development in ...e speaker at a conference at,Massachusetts School ...
Breaking Medicine News(10 mins):Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Ira Magaziner Joins Leaders in Peace Psychology at MSPP to Explore Ways to Transform Violence, Heal Families, Communities and World 2Health News:Ira Magaziner Joins Leaders in Peace Psychology at MSPP to Explore Ways to Transform Violence, Heal Families, Communities and World 3Health News:Ira Magaziner Joins Leaders in Peace Psychology at MSPP to Explore Ways to Transform Violence, Heal Families, Communities and World 4
...m the university of Michigan state that Women who ...more likely than nonsmokers to give birth// to a b...rth defect rises with the number of cigarettes tha...ors like the mother's race, age and educational le...
...gthening drug fosamax (Bifosa) was initially laude...sis. But doctors discovered that patients often st...igid dosing instructions: It was supposed to be ta...ed with plenty of water. To top it off, the drug c...
...nsity lipoprotein(LPD), lipid composition and anti...liability to oxidation of LDL derived from diabeti...re the oxidation of LDL drawn from patients with d... also sought to follow-up the effects of dietary b...
...hat women have yet another good reason to exercise...for so many things. It reduces our risk of heart d...s levels. Now a new study says it's also good for ... Right now screening tests for ovarian cancer are ...
Other Medicine News:
(Date:9/4/2008)... Data for Ipilimumab to be Presented, PRINCETON, ...nc.,(Nasdaq: MEDX ) announced today that nine cli... anti-CTLA-4 antibody, in melanoma are scheduled t...ress of the European Society,for Medical Oncology ...lm.,Many of the following abstracts will include u...
(Date:9/4/2008)... on Schedule with Two Abstracts Accepted for P...vember 2008, BRIDGEWATER, N.J., Sept. 4 /PRNewswi... pharmaceutical company focused on the treatment o...unced the appointment of,Peter L. Garrambone, Jr. ...mbone,s career includes more than 50 pharmaceutica...
(Date:9/3/2008).../- Simcere,Pharmaceutical G...plier of,branded generic pharmaceuticals and manuf...t Endu (also known as Endostar) in China,announce...udy., At the request of the SFDA, Simcere initiat...he safety and therapeutic efficacy of Endu, a modi...
(Date:9/3/2008)...onal Vascular Disease Awareness Month, CHARLOTTES...maceuticals,LLC, a clinical-stage drug-development...nt of unmet medical needs, announced today that it...ical trial of its lead drug,candidate trans sodium...881,on the clinicaltrials.gov Website, is investig...
Breaking Medicine Technology:Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Inverness Medical Innovations to Acquire Redwood Toxicology Laboratory 8672 1Inverness Medical Innovations to Acquire Redwood Toxicology Laboratory 8672 2Inverness Medical Innovations to Acquire Redwood Toxicology Laboratory 8672 3How to Survive an Unexpected Trip to the Hospital During Christmas and New Years 8668 1How to Survive an Unexpected Trip to the Hospital During Christmas and New Years 8668 2Indevus Comments on Bayer Healthcare Discontinuation of Viadur 28R 29 2352 1Indevus Comments on Bayer Healthcare Discontinuation of Viadur 28R 29 2352 2Indevus Comments on Bayer Healthcare Discontinuation of Viadur 28R 29 2352 3VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board 2348 1VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board 2348 2VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board 2348 3VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board 2348 4
...rstCall/ -- CEL-SCI,CORPORATION announces that CEL...an influenza antigen in combination with MAS-1, a,...ngs were,presented on May 23, 2007 by Dr. Daniel Z...lar Immunology at CEL-SCI at the,American Society ...,Toronto, Canada. , This new finding with CEL-1000...
...tCall/ -- Shire plc,announced today that DAYTRANA(...ntion Deficit Hyperactivity Disorder (ADHD) patch,... of ADHD in both,male and female children aged 6 t...ported at the American Psychiatric Association,(AP...udies have examined gender differences in the,resp...
Other Medicine Technology:CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response,Against Avian Flu Antigen in Animals 2Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 2Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 3Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 4Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 5Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 6Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 7Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 8
...nts with,predominantly classic subfoveal choroid... the Opal Photoactivator from,Lumenis. Developed...or injection) therapy, the Opal Photoactivator,o...tures,that ensure the highest level of patient c...
Features soft, low friction sheath that extends beyond the tip.
Designed to retain the desired curve during oral intubation.
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box.
Medicine Products: